Viewing Study NCT07165769


Ignite Creation Date: 2025-12-24 @ 11:08 PM
Ignite Modification Date: 2025-12-25 @ 8:41 PM
Study NCT ID: NCT07165769
Status: RECRUITING
Last Update Posted: 2025-12-18
First Post: 2025-09-03
Is NOT Gene Therapy: False
Has Adverse Events: False

Brief Title: Zanubrutinib, Obinutuzumab, and Lenalidomide (ZGR) in the Treatment of Newly Diagnosed Splenic B-cell Lymphoma With Prominent Nucleoli (SBLPN): A Prospective, Open-label, Single-arm Clinical Trial
Sponsor: Institute of Hematology & Blood Diseases Hospital, China
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module